Background
Phase III, randomized, multicenter trial. 95 patients with a single brain metastasis who underwent complete surgical resection (verified by postoperative MRI) were randomized to postoperative WBRT vs observation. Study enrolled 1989–1997. Established whether WBRT after complete resection is necessary.
Interventions and follow up
Arm A: Whole-brain radiotherapy (WBRT) after complete resection (dose not specified per protocol, typically 50.4 Gy)
Arm B: Observation after complete resectio
Primary endpoint: Recurrence of tumor anywhere in the brai
mFollow up: Median 48 weeks (WBRT) and 43 weeks (observation)
Arm B: Observation after complete resectio
Primary endpoint: Recurrence of tumor anywhere in the brai
mFollow up: Median 48 weeks (WBRT) and 43 weeks (observation)
Results
Brain recurrence (any site): 18% (WBRT) vs 70% (observation), P<.001
Local (surgical site) recurrence: 10% vs 46%, P<.001
Distant brain recurrence: 14% vs 37%, P<.01
Neurologic death: 14% vs 44%, P=.003
Overall survival: No significant difference
Functional independence: No significant difference
Local (surgical site) recurrence: 10% vs 46%, P<.001
Distant brain recurrence: 14% vs 37%, P<.01
Neurologic death: 14% vs 44%, P=.003
Overall survival: No significant difference
Functional independence: No significant difference
Adverse events
Main adverse events: WBRT associated with alopecia and fatigue. No significant difference in neurocognitive function at time of study (cognitive endpoints not formally assessed). No unexpected toxicities. Radiation necrosis rate not separately reported.
Conclusions
Postoperative WBRT after complete resection of a single brain metastasis reduces brain recurrence and neurologic death compared with observation, but does not improve OS or functional independence. For decades this trial established WBRT as standard after BM resection — a paradigm later shifted by N107C (SRS to cavity) and EORTC 22952 (showing no QoL benefit from WBRT).
Key Limitations
Key Limitations: No formal neurocognitive testing — the cognitive harm of WBRT (now well documented) was not measured. OS equivalence means the trial was underpowered to detect a survival difference if one existed. Modern practice has largely replaced WBRT with SRS to the cavity (Alliance N107C) to preserve cognition. The trial reflects 1989–1997 technology — salvage options were far more limited then.
Clinical Context
Patchell II established WBRT after resection as standard of care for ~15 years. Alliance N107C (2017) subsequently demonstrated that post-op SRS to the surgical cavity preserves cognition without compromising OS, making cavity SRS the current standard of care over WBRT in most patients with resected BM. WBRT is now generally reserved for patients with poor prognosis, extensive metastatic burden, or leptomeningeal disease.
References